SecBot SecBot
8-K ·Filed Nov 9, 2026

VIR

Vir Biotechnology, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed7d 15h ago SEC0001628280-26-071908
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The Phase 3 ECLIPSE 1 data support a potential regulatory filing for elebsiran + tobevibart in chronic hepatitis delta. Monitor the upcoming investor call for details on the regulatory pathway and commercialization timeline. The SOLSTICE finite treatment data, while early, suggest potential for a functional cure, which would be transformative if confirmed in larger studies.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

VIR drug pipeline →

elebsiran

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 ECLIPSE 1 results are positive, regulatory filings could follow in 2027, with potential FDA approval in 2027-2028 given the Breakthrough Therapy designation enabling expedited review.
Next catalyst
None dated

What to watchThe pivotal Phase 3 ECLIPSE 1 topline results for elebsiran plus tobevibart in chronic hepatitis delta will be presented as a late-breaking oral at AASLD on November 8, 2026, with an investor call on November 9. Positive data would support regulatory filings and validate the combination against bulevirtide; negative or mixed results would severely damage the company's lead program thesis. The stock surged ~11% on November 6 ahead of the readout, reflecting anticipation.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$13.65
T+0 close · Nov 9, 2026 · via day close
Latest settled
−29.79%
T+5 · $9.58
Vs SPY
−28.10%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $13.65entry
  2. T+1 · 7d ago −3.63%α −3.26% · $13.15
  3. T+5 · 17h ago −29.79%α −28.10% · $9.58
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology announced positive Phase 3 ECLIPSE 1 topline results for its combination regimen of elebsiran and tobevibart in chronic hepatitis delta, meeting the primary endpoint with a 44% response rate vs 0% in the delayed treatment group (p<0.0001). Expanded Phase 2 SOLSTICE data showed 100% of patients reaching undetectable viremia at Week 96, and an exploratory finite treatment analysis showed all 10 patients who discontinued treatment achieved SVR12. The data were presented at AASLD on November 8, 2026.

Key Facts

  • Phase 3 ECLIPSE 1 primary endpoint met: 44% undetectable virus + ALT normalization at Week 48 vs 0% in delayed treatment group (p<0.0001)
  • Key secondary endpoint: 79% undetectable virus at Week 48 vs 0% (p<0.0001)
  • 100% virologic response (HDV RNA TND or 2 log10 reduction) in active arm vs 0% in control
  • Phase 2 SOLSTICE Week 96: 100% (28/28) of patients on combination therapy reached undetectable viremia
  • Exploratory finite treatment analysis: all 10 patients who discontinued achieved SVR12, 7 achieved SVR24, 1 achieved SVR48
  • Regimen well-tolerated: one Grade 3 TRAE (neutrophil count decrease, resolved in 15 days), no treatment discontinuations
  • Trial enrolled 124 patients randomized 2:1, including patients with advanced disease and cirrhosis

Financial Impact

Positive Phase 3 data in chronic hepatitis delta, a disease with no approved therapies, could unlock a significant commercial opportunity; market cap is $1.9B

revenuemarket_cap

Risk Factors

  • SOLSTICE finite treatment data are preliminary, based on only 10 patients, and have not undergone formal data cut; results may not be representative
  • Regulatory approval is not guaranteed; the FDA may require additional trials or longer follow-up data
  • Commercialization in chronic hepatitis delta faces challenges including patient identification, market access, and potential competition from other investigational therapies

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-071908
Document: 0001628280-26-071908-index-headers.html0001628280-26-071908
Document: 0001628280-26-071908-index.html0001628280-26-071908
Document: 0001628280-26-071908.txt0001628280-26-071908

Track record

36 reports on VIR

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026